文献速递胃肠动力与功能性疾病

肠易激综合征患者的死亡风险:全国性前瞻性队列研究结果

Mortality Risk in Irritable Bowel Syndrome: Results From a Nationwide Prospective Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究在瑞典开展全国性匹配人群队列研究,纳入45,524例肠易激综合征(IBS)患者,与年龄性别匹配的参考个体(n=217,316)及兄弟姐妹(n=53,228)比较死亡风险。随访期间IBS患者死亡3,290例(9.4/1,000人年),参考个体死亡13,255例(7.9/1,000人年),粗分析HR为1.10(95%CI=1.05-1.14),但多因素调整后IBS与死亡无关(HR=0.96;95%CI=0.92-1.00)。未行结直肠活检的IBS患者死亡风险亦未增加(HR=1.02;95%CI=0.99-1.06)。

要点

  • 多因素调整后IBS与死亡风险无关(HR=0.96;95%CI=0.92-1.00)。
  • 与兄弟姐妹比较,IBS患者死亡风险估计为中性。
  • 未行结直肠活检的IBS患者死亡风险未增加(HR=1.02;95%CI=0.99-1.06)。

核心结论

  • IBS似乎并不增加死亡风险。

研究设计与样本

  • 瑞典全国性、匹配、基于人群的队列研究,纳入2002至2016年确诊IBS且行结直肠活检的患者45,524例。
  • 参考个体为来自一般人群的年龄性别匹配个体(n=217,316),并另有兄弟姐妹(n=53,228)作为比较。
  • 另对41,427例未行结直肠活检的IBS患者进行死亡分析,采用Cox回归估计死亡风险比(HR)。

主要发现

  • 随访期间IBS患者死亡3,290例(9.4/1,000人年),参考个体死亡13,255例(7.9/1,000人年),粗HR为1.10(95%CI=1.05-1.14)。
  • 多因素调整后IBS与死亡无关(HR=0.96;95%CI=0.92-1.00)。
  • 与兄弟姐妹比较时,IBS患者死亡风险估计为中性。
  • 活检黏膜外观对IBS患者死亡仅有边际影响。
  • 未行结直肠活检的IBS患者死亡风险未增加(HR=1.02;95%CI=0.99-1.06)。

临床怎么用

  • 对于IBS患者,死亡担忧不应作为驱动反复检查的主要理由,可据此安抚患者。
  • 黏膜外观对死亡风险影响有限,提示IBS患者常规活检的预后价值可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Mortality concern is a frequent driver of care seeking in patients with irritable bowel syndrome (IBS). Data on mortality in IBS are scarce, and population-based studies have been limited in size. We examined mortality in IBS. METHODS: A nationwide, matched, population-based cohort study was conducted in Sweden. We identified 45,524 patients undergoing a colorectal biopsy at any of Sweden's 28 pathology departments and with a diagnosis of IBS from 2002 to 2016 according to the National Patient Register, a nationwide registry of inpatient and outpatient specialty care. We compared the mortality risk between these individuals with IBS and age- and sex-matched reference individuals (n = 217,316) from the general population and siblings (n = 53,228). In separate analyses, we examined the role of mucosal appearance for mortality in IBS. Finally, we examined mortality in 41,427 patients with IBS not undergoing a colorectal biopsy. Cox regression estimated hazard ratios (HRs) for death. RESULTS: During follow-up, there were 3,290 deaths in individuals with IBS (9.4/1,000 person-years) compared with 13,255 deaths in reference individuals (7.9/1,000 person-years), resulting in an HR of 1.10 (95% confidence interval [CI] = 1.05-1.14). After adjustment for confounders, IBS was not linked to mortality (HR = 0.96; 95% CI = 0.92-1.00). The risk estimates were neutral when patients with IBS were compared with their siblings. The underlying mucosal appearance on biopsy had only a marginal impact on mortality, and patients with IBS not undergoing a colorectal biopsy were at no increased risk of death (HR = 1.02; 95% CI = 0.99-1.06). DISCUSSION: IBS does not seem to confer an increased risk of death.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Staller K, Olén O, Söderling J, et al. Mortality Risk in Irritable Bowel Syndrome: Results From a Nationwide Prospective Cohort Study. Am J Gastroenterol. 2020. PMID: 32108661. doi:10.14309/ajg.0000000000000573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。